Extent and Management of cardiovascular risk factors in patients with type 2 diabetes and serious mental illness

Journal of Nervous and Mental Disease

Volumn 194, Issue 6, 2006, Pages 404-410

  Kreyenbuhl, Julie ^a,b   Dickerson, Faith B ^c   Medoff, Deborah R ^a,b   Brown, Clayton H ^a,b   Goldberg, Richard W ^a,b   Fang, LiJuan ^a   Wohlheiter, Karen ^a   Mittal, Leena P ^a   Dixon, Lisa B ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VA Capitol Health Care Network   (United States)

^c SHEPPARD PRATT HEALTH SYSTEM   (United States)

Author keywords

Cardiovascular risk; Metabolic syndrome; Serious mental illness; Type 2 diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; SCHIZOPHRENIA;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CHOLESTEROL; COMORBIDITY; DEPRESSIVE DISORDER, MAJOR; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA;

EID: 33745268502     PISSN: 00223018     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nmd.0000221177.51089.7d     Document Type: Article

References (43)

1. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications, part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med. 15:539-553.
2. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, Weiden PJ (1999) Antipsychotic-induced weight gain: A comprehensive research synthesis. Am J Psychiatry. 156:1686-1696.
3. American Diabetes Association (2003) Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 6:917-932.
4. American Diabetes Association (2004) Standards of medical care in diabetes. Diabetes Care. 27(suppl 1):S15-S35.
5. Armitage J, Bowman L (2004) Cardiovascular outcomes among participants with diabetes in the recent large statin trials. Curr Opin Lipidol. 15:439-446.
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl J Med. 345:861-869.
7. Brown S, Inskip H, Barraclough B (2000) Causes of the excess mortality of schizophrenia. Br J Psychiatry. 177:212-217.
8. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, Investigators CARDS (2004) Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet. 364:685-696.
9. Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet. 361:2005-2016.
10. Daumit GL, Clark JM, Steinwachs DM, Graham CM, Lehman A, Ford DE (2003) Prevalence and correlates of obesity in a community sample of individuals with severe and persistent mental illness. J Nerv Ment Dis. 191:799-805.
11. Daumit GL, Goldberg RW, Anthony C, Dickerson FB, Brown CH, Kreyenbuhl J, Wohlheiter K, Dixon LB (2005) Physical activity patterns in adults with severe mental illness. J Nerv Ment Dis. 193:641-646.
12. de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM (1995) Schizophrenia and smoking: An epidemiological survey in a state hospital. Am J Psychiatry. 152:453-455.
13. Dickerson FB, McNary SW, Brown CH, Kreyenbuhl J, Goldberg RW, Dixon LB (2003) Somatic healthcare utilization among adults with serious mental illness who are receiving community psychiatric services. Med Care. 41:560-570.
14. Dixon LB, Kreyenbuhl JA, Dickerson FB, Donner TW, Brown CH, Wohlheiter K, Postrado L, Goldberg RW, Fang L, Marano C, Messias E (2004) A comparison of Type 2 diabetes outcomes among persons with and without severe mental illness. Psychiatr Serv. 55:892-900.
15. Dixon LB, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A (2000) Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 26:903-912.
16. Druss BG, Bradford DW, Rosenheck RA, Radford MJ, Krumholz HM (2000) Mental disorders and use of cardiovascular procedures after myocardial infarction. JAMA. 283:506-511.
17. Druss BG, Rosenheck RA (1998) Mental disorders and access to medical care in the United States. Am J Psychiatry. 155:1775-1777.
18. Druss BG, Rosenheck RA, Desai MM, Perlin JB (2002) Quality of preventive medical care for patients with mental disorders. Med Care. 40:129-136.
19. Engelgau MM, Geiss LS, Saaddine JB, Boyle JP, Benjamin SM, Gregg EW, Tierney EF, Rios-Burrows N, Mokdad AH, Ford ES, Imperatore G, Narayan KM (2004) The evolving diabetes burden in the United States. Ann Intern Med. 140:945-950.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 285:2486-2497.
21. Grant RW, Buse JB, Meigs JB (2005) Quality of diabetes care in US academic medical centers. Diabetes Care. 28:337-442.
22. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, Pasternak RC, Smith SC Jr, Stone NJ, National Heart, Lung and Blood Institute, American College of Cardiology Foundation, American Heart Association (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 110:227-239.
23. Kennedy AG, Maclean CD, Littenberg B, Ades PA, Pinckney RG (2005) The challenge of achieving national cholesterol goals in patients with diabetes. Diabetes Care. 28:1029-1034.
24. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, Herman WH, Marrero DG, Narayan KM, Safford MM, Thompson T, Mangione CM (2004) Diabetes care quality in the Veterans Affairs health care system and commercial managed care: The TRAID study. Ann Intern Med. 141:272-281.
25. Kurtz TW, Pravenec M (2004) Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system. J Hypertens. 22:2253-2261.
26. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT (2002) The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 288:2709-2716.
27. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA (2002) Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol. 156:1070-1077.
28. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 160:290-296.
29. McCreadie RG (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study. Br J Psychiatry. 183:534-539.
30. Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, O'Leary DH, Genuth S, Diabetes Control and Complications Trial, Epidemiology of Diabetes Interventions and Complications Research Group (2003) Intensive diabetes therapy and carotid intima-media thickness in Type 1 diabetes mellitus. N Engl J Med. 348:2294-2303.
31. Nau DP, Garber MC, Herman WH (2004) The intensification of drug therapy for diabetes and its complications: Evidence from 2 HMOs. Am J Manag Care. 10:118-123.
32. Nau DP, Mallya U (2005) Sex disparity in the management of dyslipidemia among patients with type 2 diabetes mellitus in a managed care organization. Am J Manag Care. 11:69-73.
33. Newman SC, Bland RC (1991) Mortality in a cohort of patients with schizophrenia: A record linkage study. Can J Psychiatry. 36:239-245.
34. Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000) Mortality and causes of death in schizophrenia in Stockholm County, Sweden. Schizophr Res. 45:21-28.
35. Petersen LA, Normand SL, Druss BG, Rosenheck RA (2003) Process of care and outcome after acute myocardial infarction for patients with mental illness in the VA health care system: Are there disparities? Health Serv Res. 38:41-63.
36. Safford M, Eaton L, Hawley G, Brimacombe M, Rajan M, Li H, Pogach L (2003) Disparities in use of lipid-lowering medications among people with Type 2 diabetes mellitus. Arch Intern Med. 163:922-928.
37. Saydah SH, Fradkin J, Cowie CC (2004) Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 291:335-342.
38. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden SH (2004) Meta-analysis: Glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 141:421-431.
39. Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J (2005) Reduction in cardiovascular events with atorvastatin in 2,532 patients with Type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Diabetes Care. 28:1151-1157.
40. Stamler J, Vaccaro O, Neaton JD, Wentworth D (1993) Diabetes, other risk factors and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 16:434-444.
41. Timpe EM, Amarshi N, Reed P (2004) Evaluation of angiotension-converting enzyme inhibitor use in patients with type 2 diabetes in a state managed care plan. Am J Manag Care. 10:124-129.
42. Wexler DJ, Grant RW, Meigs JB, Nathan DM, Cagliero E (2005) Sex disparities in treatment of cardiac risk factors in patients with type 2 diabetes. Diabetes Care. 28:514-520.
43. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation. 97:1837-1847.